JPWO2019239144A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019239144A5 JPWO2019239144A5 JP2020570030A JP2020570030A JPWO2019239144A5 JP WO2019239144 A5 JPWO2019239144 A5 JP WO2019239144A5 JP 2020570030 A JP2020570030 A JP 2020570030A JP 2020570030 A JP2020570030 A JP 2020570030A JP WO2019239144 A5 JPWO2019239144 A5 JP WO2019239144A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sarna
- additional activator
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 59
- 239000012190 activator Substances 0.000 claims 28
- 108091029810 SaRNA Proteins 0.000 claims 23
- 229940078677 sarna Drugs 0.000 claims 23
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 10
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 10
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 10
- 150000003384 small molecules Chemical group 0.000 claims 9
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 7
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 7
- 229960003787 sorafenib Drugs 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 229940125408 FGFR4 inhibitor Drugs 0.000 claims 6
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 6
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 108091081021 Sense strand Proteins 0.000 claims 6
- 230000000692 anti-sense effect Effects 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 claims 3
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 238000007674 radiofrequency ablation Methods 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 229940126533 immune checkpoint blocker Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 2
- 229960003784 lenvatinib Drugs 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024087660A JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685627P | 2018-06-15 | 2018-06-15 | |
| US62/685,627 | 2018-06-15 | ||
| US201862731532P | 2018-09-14 | 2018-09-14 | |
| US62/731,532 | 2018-09-14 | ||
| US201962821533P | 2019-03-21 | 2019-03-21 | |
| US62/821,533 | 2019-03-21 | ||
| PCT/GB2019/051654 WO2019239144A1 (en) | 2018-06-15 | 2019-06-14 | Combination therapies comprising c/ebp alpha sarna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087660A Division JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527651A JP2021527651A (ja) | 2021-10-14 |
| JPWO2019239144A5 true JPWO2019239144A5 (https=) | 2022-06-20 |
| JP2021527651A5 JP2021527651A5 (https=) | 2022-06-20 |
Family
ID=67070873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570030A Pending JP2021527651A (ja) | 2018-06-15 | 2019-06-14 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
| JP2024087660A Withdrawn JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087660A Withdrawn JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210254069A1 (https=) |
| EP (1) | EP3807410A1 (https=) |
| JP (2) | JP2021527651A (https=) |
| CN (1) | CN112543809A (https=) |
| AU (1) | AU2019285344A1 (https=) |
| CA (1) | CA3102334A1 (https=) |
| WO (1) | WO2019239144A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020330133A1 (en) * | 2019-08-14 | 2022-03-17 | Lonza Sales Ag | Extracellular vesicle-ASO constructs targeting CEBP/beta |
| KR20230009354A (ko) * | 2020-05-12 | 2023-01-17 | 아스트라제네카 아베 | 면역 체크포인트 억제제 항체를 사용한 암 치료용 방법 및 조합물 |
| CN111876390B (zh) * | 2020-08-12 | 2021-04-09 | 湖南南华爱世普林生物技术有限公司 | 负载化合物的转基因干细胞外泌体在制备药物或美白化妆品中的用途 |
| EP4329777A1 (en) * | 2021-04-28 | 2024-03-06 | MiNA Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
| WO2024175887A1 (en) * | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| AU5613999A (en) | 1998-09-18 | 2000-04-10 | University Of British Columbia, The | Pharmaceutical compositions of vanadium biguanide complexes and their use |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1854880A1 (en) | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| CA2604532C (en) | 2005-04-15 | 2017-03-07 | The Regents Of The University Of California | Small activating rna molecules and methods of use |
| JP5066095B2 (ja) | 2005-11-17 | 2012-11-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節 |
| US8748815B2 (en) | 2006-08-31 | 2014-06-10 | Hermes Microvision, Inc. | Method and system for detecting or reviewing open contacts on a semiconductor device |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| EP2421972A2 (en) | 2009-04-24 | 2012-02-29 | The Board of Regents of The University of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
| CN101941001B (zh) | 2009-07-03 | 2014-04-02 | 3M创新有限公司 | 亲水涂层、制品、涂料组合物和方法 |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| KR20130132795A (ko) | 2010-10-08 | 2013-12-05 | 미나 테라퓨틱스 리미티드 | 짧은 rna 분자 |
| EP4060043A1 (en) | 2011-06-21 | 2022-09-21 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| CA3236835A1 (en) | 2013-11-22 | 2015-05-28 | Mina Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
| US10912790B2 (en) * | 2015-04-22 | 2021-02-09 | Mina Therapeutics Limited | C/EBP alpha saRNA compositions and methods of use |
| ES2972458T3 (es) * | 2016-02-10 | 2024-06-12 | Bioinvent Int Ab | Combinación de anticuerpo humano anti-FGFR4 y sorafenib |
| WO2018049233A1 (en) * | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
-
2019
- 2019-06-14 AU AU2019285344A patent/AU2019285344A1/en not_active Abandoned
- 2019-06-14 EP EP19733859.3A patent/EP3807410A1/en active Pending
- 2019-06-14 CA CA3102334A patent/CA3102334A1/en active Pending
- 2019-06-14 WO PCT/GB2019/051654 patent/WO2019239144A1/en not_active Ceased
- 2019-06-14 CN CN201980040237.3A patent/CN112543809A/zh active Pending
- 2019-06-14 US US17/252,593 patent/US20210254069A1/en not_active Abandoned
- 2019-06-14 JP JP2020570030A patent/JP2021527651A/ja active Pending
-
2024
- 2024-05-30 JP JP2024087660A patent/JP2024103632A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527651A5 (https=) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JP2018521135A5 (https=) | ||
| JP6158833B2 (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
| Maaser et al. | A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators | |
| Qian et al. | Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth | |
| Zhang et al. | Effects and significance of formononetin on expression levels of HIF-1α and VEGF in mouse cervical cancer tissue | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Li et al. | Cancer differentiation inducer chlorogenic acid suppresses PD-L1 expression and boosts antitumor immunity of PD-1 antibody | |
| CN104099333B (zh) | 用于乳腺癌的piRNA | |
| JPWO2019239144A5 (https=) | ||
| JP2020508699A (ja) | 男性型脱毛標的遺伝子の発現を抑制する非対称ｓｉＲＮＡ | |
| RU2535993C2 (ru) | Молекула rnai, нацеливающая тимидилатсинтазу и ее применение | |
| Claude-Taupin et al. | Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies | |
| JP2016537400A5 (https=) | ||
| CN102816792B (zh) | 一种调控热休克蛋白70表达、数量及活性的方法及其应用 | |
| WO2015069906A2 (en) | Modified dna quadruplex-forming oligonucleotides and methods of use | |
| CN117838691B (zh) | 贝曲沙班或其药学上可接受的盐在用于制备抗肿瘤或激活干扰素药物中的用途 | |
| JP2016533190A5 (https=) | ||
| US11149271B2 (en) | Method and pharmaceutical composition for treating cancer | |
| JP2016515804A (ja) | 悪性胸膜中皮腫を治療するためのマイクロｒｎａを基にしたアプローチ | |
| Nakanishi et al. | Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafur as evaluated using LacZ gene-tagged Lewis lung carcinoma cell | |
| JP2021500026A5 (https=) | ||
| Haghnavaz et al. | Paclitaxel may inhibit epithelial-mesenchymal transition properties of triple-negative breast cancer cell line via altering the expression of EMT-promoting and–inhibiting microRNAs |